Sera Prognostics, Inc. (SERA) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. Financial performance is weak, with a significant revenue decline, though cash reserves remain strong. The company is making strategic moves, like Medicaid pilots and European expansion, but faces regulatory and payer engagement risks. The Q&A reveals confidence in Medicaid progress and the upcoming PRIME publication, but management's reluctance to disclose economic specifics and guideline timelines adds uncertainty. Overall, the sentiment is neutral, as positive strategic developments are offset by financial challenges and uncertainties.
Key Financial Performance
Net Revenue $16,000 for Q3 2025, compared to $29,000 in Q3 2024. The decrease is due to the early stage of commercialization efforts.
Deferred Revenue Increased by $100,000 due to a prepayment from the first Medicaid pilot in Nevada.
Total Operating Expenses $9.0 million for Q3 2025, compared to $8.9 million in Q3 2024. The slight increase is attributed to targeted commercial activities and strategic headcount additions.
Research and Development Expenses $3.3 million for Q3 2025, down from $3.5 million in Q3 2024. The decrease is primarily due to lower clinical study costs following the completion of the pivotal PRIME study.
Selling, General and Administrative Expenses $5.7 million for Q3 2025, up from $5.4 million in Q3 2024. The increase is due to investments in targeted commercial activities and strategic headcount additions.
Net Loss $7.8 million for Q3 2025, compared to $7.9 million in Q3 2024. The slight decrease reflects a focus on managing capital resources.
Cash, Cash Equivalents, and Available-for-Sale Securities Approximately $102.4 million as of September 30, 2025, reflecting a strong balance sheet to support growth strategy.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
PreTRM Test: Continued progress in adoption, supported by PRIME study outcomes. Focused on achieving payer coverage, physician education, and patient awareness. Demonstrated efficacy through health economics data and clinical studies like PRIME and AVERT.
Geographic Expansion: Commercial strategy focused on select regions with strong alignment in payer discussions, local opinion leaders, and early adopter institutions. Active engagement with 13 states, including Nevada, Texas, and Massachusetts, covering 33% of U.S. births and 35% of Medicaid births annually.
European Market: Exploring opportunities in Europe with ongoing discussions with regulatory bodies. Submission of dossiers planned for early 2026.
Medicaid Pilot Programs: First Medicaid pilot in Nevada is live, with active patient enrollment. Engaging with 10 payers across 13 states to drive adoption and coverage.
Leadership Appointments: New Chief Medical Officer and Head of Commercial Operations appointed to accelerate PreTRM Test adoption and support clinical integration.
Commercialization Strategy: Two-pronged approach targeting state engagement and payer-driven adoption. Focus on Medicaid and commercial plans, value-based care arrangements, and physician advocacy to build adoption.
Guideline Inclusion: Long-term goal to achieve guideline inclusion for PreTRM Test, enabling national scaling and broader awareness.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Adoption Challenges: The company faces challenges in achieving widespread adoption of the PreTRM Test, as it requires payer coverage, physician education, and patient awareness. The adoption process is slow, with Medicaid pilot programs taking approximately 24 months or more to yield results.
Regulatory and Reimbursement Delays: The path to state Medicaid coverage decisions is lengthy, involving multiple steps such as pilot program data collection, claims data analysis, and stakeholder engagement. This delay could impact the company's ability to scale its operations and revenue growth.
Financial Performance: The company reported a net revenue of only $16,000 for the quarter, a decline from $29,000 in the same period last year. This low revenue, coupled with a net loss of $7.8 million, highlights financial challenges in the short term.
Operational Costs: Operating expenses remain high at $9.0 million for the quarter, with significant spending on selling, general, and administrative activities, which could strain financial resources if revenue growth does not materialize.
Competitive and Market Pressures: The company is targeting a niche market with its PreTRM Test, and its success depends on achieving guideline inclusion and broader payer coverage. Failure to achieve these milestones could limit market penetration and revenue potential.
Dependence on Medicaid and Payer Engagement: The company's strategy heavily relies on Medicaid and payer-driven adoption. Any delays or setbacks in these areas could significantly impact its commercialization efforts and financial performance.
European Market Entry Risks: While exploring opportunities in Europe, the company faces regulatory hurdles and uncertainties in gaining approval and market acceptance in a new region.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future publication of PRIME study results: The company plans to publish the full results of the PRIME study in a peer-reviewed journal by the end of the year, followed by an investor and analyst event to discuss outcomes and new data points.
Data publication cadence: Sera Prognostics intends to maintain a steady cadence of data publications and presentations, focusing on health economic benefits, subpopulation analysis, and Medicaid cost savings.
Commercial strategy and Medicaid pilots: The company is focusing on geographically targeted adoption of the PreTRM Test, starting with Medicaid pilot programs in six states, including Nevada, Texas, and Massachusetts. The first pilot in Nevada is actively enrolling patients, and discussions have expanded to 13 states.
Timeline for Medicaid coverage decisions: The path to state Medicaid coverage decisions is expected to take approximately 24 months or more, involving pilot program data collection, analysis, and presentation to stakeholders.
Expansion to Europe: Sera Prognostics is engaged in discussions with European regulatory bodies and plans to submit regulatory dossiers in early 2026.
Leadership appointments to support growth: The company has appointed a Chief Medical Officer and Head of Commercial Operations to accelerate PreTRM Test adoption and establish it as a standard of care.
National scaling post-guideline inclusion: The company plans to scale nationally with a field sales force and broader payer coverage after achieving guideline inclusion for the PreTRM Test.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Do you feel like progress is on track for the Medicaid pilots, particularly in Nevada, and when do you expect to have all 6 pilots signed up?
A:The company is on track with the Medicaid pilots. One pilot is launched and recruiting, another is in contracting, and they expect a couple more shortly. They are in active discussions with payers in other states and will communicate progress once the pilots are up and running.
Q:How big are the Medicaid pilots, and what are the economics during the pilot phase?
A:The typical size of a pilot is a few hundred patients, but some states and payers are considering statewide contracts involving thousands of patients. The company is also exploring value-based healthcare arrangements. Specific economic details were not disclosed, but the company is satisfied with the price realization in early engagements.
Q:Are you collecting full price for the pilots, or is there a discount?
A:Specifics were not disclosed, but the company is happy with the price realization in early engagements with payers and state Medicaids.
Q:Do you still feel confident that the PRIME publication will come before year-end, and what additional data will be included?
A:The company is confident the PRIME publication will be released in the coming weeks, ideally before year-end. Specific data cannot be disclosed before publication, but new insights from reviewer engagement and additional mined data will be included.
Q:What is the timeline for guideline inclusion post-PRIME publication, and what will be the focus until then?
A:The timeline for guideline inclusion is estimated at 24 to 36 months post-publication. Until then, the focus will be on geographic density of adoption in target states, achieving policy coverage, value-based care contracts, and physician adoption. Post-guidelines, the focus will shift to nationwide commercialization.
Q:What are your plans once the PRIME publication is released, and how prepared is the organization?
A:The organization is prepared for the PRIME publication release. Plans include initiating policy reviews by payers, disseminating information to clinicians through conferences and events, and driving physician adoption in target states. The company has made key hires and is ready to execute its post-publication plan.
Q:How should we think about the commercial team build-out and SG&A expenses in 2026?
A:The commercial team will expand as coverage is established in new states, with additional sales reps and medical science liaisons added in waves. SG&A expenses are expected to remain relatively flat, with a significant increase in sales and marketing activities.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the economic terms of the Medicaid pilots, including whether full price is being collected or if there are discounts. Additionally, they did not disclose specific data from the upcoming PRIME publication, citing the need to wait until the publication date.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Dr
Head
Health
Medicaid pilot
Medicaid plan
Nevada
Outcomes
Test adoption
adoption outcome
alignment
approach
base
birth risk
claim
complication
cost saving
coverage Medicaid
coverage decision
coverage physician
effort
engagement state
engagement wave
guideline inclusion
health economics
institution
marketing
momentum
payer coverage
physician adoption
presentation
press release
provider
region
stage
state coverage
state discussion
state engagement
stride
track
traction
value care
visibility
wave state
SERA Transcript
Sera Prognostics, Inc. (SERA) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call reveals several concerns: declining revenue, increased operating expenses, and a slight rise in net loss, indicating financial struggles. The shift from R&D to commercial efforts could hinder future innovation. Additionally, challenges in payer engagement and European market entry pose risks. While management remains optimistic about partnerships and Medicaid coverage, the lack of specific metrics and timelines, coupled with potential delays, adds uncertainty. These factors suggest a negative sentiment, likely impacting the stock price negatively in the short term.
Sera Prognostics, Inc. (SERA) Q4 2025 Earnings Call Transcript
Unknown3-18
The earnings call reflects mixed sentiments. While there are positive aspects like disciplined expense management and promising partner programs, the company faces significant commercialization challenges and financial losses. The Q&A section indicates some optimism with stakeholder engagement and strategic partnerships, yet uncertainties in payer coverage and market access persist. The financial metrics reveal modest revenue and ongoing losses, with a stable cash position but slow growth. These factors balance out, leading to a neutral stock price prediction in the short term.
Sera Prognostics, Inc. (SERA) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed picture. Financial performance is weak, with a significant revenue decline, though cash reserves remain strong. The company is making strategic moves, like Medicaid pilots and European expansion, but faces regulatory and payer engagement risks. The Q&A reveals confidence in Medicaid progress and the upcoming PRIME publication, but management's reluctance to disclose economic specifics and guideline timelines adds uncertainty. Overall, the sentiment is neutral, as positive strategic developments are offset by financial challenges and uncertainties.
Sera Prognostics, Inc. (SERA) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call highlights several concerns: a decline in net revenue, high operating expenses, and challenges in regulatory and reimbursement approvals. The Q&A reveals delays in guideline inclusion and vague responses on sales force expansion. Despite plans for European market entry, the financial strain and uncertainties overshadow potential growth. The stock price is likely to experience a negative reaction in the short term due to these factors.
SERA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
